CN Patent

CN114555088A — 包含赛乐西帕的药物组合物

Assigned to Actelion Pharmaceuticals Ltd · Expires 2022-05-27 · 4y expired

What this patent protects

本发明涉及包含2‑{4‑[N‑(5,6‑二苯基吡嗪‑2‑基)‑N‑异丙基氨基]丁氧基}‑N‑(甲磺酰基)乙酰胺(赛乐西帕(selexipag)、NS‑304、ACT‑293987)的药物组合物，这些药物组合物适用于口服施用(p.o.)。

USPTO Abstract

本发明涉及包含2‑{4‑[N‑(5,6‑二苯基吡嗪‑2‑基)‑N‑异丙基氨基]丁氧基}‑N‑(甲磺酰基)乙酰胺(赛乐西帕(selexipag)、NS‑304、ACT‑293987)的药物组合物，这些药物组合物适用于口服施用(p.o.)。

Drugs covered by this patent

Patent Metadata

Patent number
CN114555088A
Jurisdiction
CN
Classification
—
Expires
2022-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.